Social Media in Pharmacovigilance: Europe starts moving

Years behind USA,
Europe starts to grow in its awareness on the potential use of social media analytics as source of hints for detecting unexpected drug effects after market approval.
Independent activities have been launched in 2013-2014 from different founding bodies and with different stakeholders, with strong EU footprint, of which hereafter just few are reported.
EU IMI Project WEB-RADR ( web-radr.eu), amining at mobile application and automatic text mining for identification of potential adverse drug events.
French-founded ADR-Prism ( adr-prism.com), with initial findings not yet published however first year report to be appearing soon.
To read the article by Luca Toldo